KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target is a research paper published in Science Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 89 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA175495
National Institutes of Health
Grant: R01DK100525
U.S. Department of Defense
Grant: BC190403
NIH HHS
Grant: S10 OD019961
NCI NIH HHS
Grant: P30 CA013330
NIDDK NIH HHS
Grant: P30 DK020541
NCATS NIH HHS
Grant: TL1 TR002557
FWCI
4.76
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway
Additional file 1 of HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway